Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies in NSCLC: Independent Conference Coverage of the 2021 ASCO Scientific Meeting
  • CME

Zofia Piotrowska, MD, MHS
Karen L. Reckamp, MD, MS
Released: August 20, 2021
Back Next

References

  1. Wu Y, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2020;383:1711-1723.
  2. Osimertinib [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2020.
  3. Wakelee HA, Altorki NK, Zhou C, et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8500.
  4. Spicer J, Wang C, Tanaka F, et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8503.
  5. Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8511.
  6. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. N Engl J Med. 2017;377:1919-1929.
  7. Antonia SJ, Villegas A, Daniel D, et al. Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC. N Engl J Med. 2018;379:2342-2350.
  8. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals; 2021.
  9. Jabbour SK, Lee KH, Frost N, et al. KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 8512.
  10. Jabbour SK, Lee KH, Frost N, et al. Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: the Phase 2 KEYNOTE-799 Nonrandomized Trial. JAMA Oncol. 2021[Epub ahead of print].
  11. Li BT, Skoulidis F, Falchook G, et al. CodeBreaK 100: registrational phase 2 trial of sotorasib in KRAS p.G12C mutated non-small cell lung cancer. Presented at: 20201 International Association for the Study of Lung Cancer World Conference on Lung Cancer; January 28-31, 2021. Abstract PS01.07.
  12. Sotorasib [prescribing information]. Thousand Oaks, CA: Amgen Inc; 2021.
  13. Skoulidis F, Li BT, Govindan R, et al. Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9003.
  14. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRASG12C mutation. N Engl J Med. 2021;384:2371-2381.
  15. Selpercatinib [prescribing information]. Indianapolis, IN: Eli Lilly and Co; 2021.
  16. Pralsetinib [prescribing information]. South San Francisco, CA: Genentech Inc; 2021.
  17. Schoffski P, Cho BC, Italiano A, et al. BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 3008.
  18. Curigliano G, Gainor JF, Griesinger F, et al. Safety and efficacy of pralsetinib in patients with advanced RET fusion-positive non-small cell lung cancer: Update from the ARROW trial. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9089.
  19. Besse B, Drilon AE, Solomon BJ, et al. Updated overall efficacy and safety of selpercatinib in patients (pts) with RET fusion+ non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9065.
  20. Bauml J, Cho BC, Park K, et al. Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9006.
  21. Janne PA, Baik CS, Su W, et al. Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9007.
  22. Meric-Bernstam F, Spira AI, Lisberg AE, et al. TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9058.
  23. Akinboro O, Vallejo JJ, Mishra-Kalyani PS, et al. Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9001.
  24. Nivolumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co; 2021.
  25. Ipilimumab [prescribing information]. Princeton, NJ: Bristol-Myers Squibb Co; 2021.
  26. Paz-Ares LG, Ciuleanu TE, Lee JS, et al. Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9016.
  27. Reck M, Ciuleanu TE, Cobo M, et al. First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9000.
  28. Tolcher AW, Reeves JA, Mckean M, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 2506.
  29. Neal JW, Kundu P, Tanaka T, et al. CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy. J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract TPS9134.
  30. Bruno DS, Hess LM, Li X, et al. Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC). J Clin Oncol. Presented at: 2021 Annual Meeting of the American Society of Clinical Oncology; June 4-8, 2021. Abstract 9005.
  31. Howlader N, Forjaz G, Mooradian MJ, et al. The effect of advances in lung-cancer treatment on population mortality. N Engl J Med. 2020;383:640-649.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings